Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

Journal of Clinical Pharmacology

Volumn 45, Issue 7, 2005, Pages 792-801

  Ng, Chee M ^a   Bruno, Rene ^a   Combs, Dan ^a   Davies, Brian ^b  

^a GENENTECH INC   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Population pharmacokinetic model; Rheumatoid arthritis; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG EXPOSURE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; POPULATION MODEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BODY SURFACE AREA; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; SEX FACTORS;

EID: 21044453927     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005277075     Document Type: Article

References (18)

1. Leget GA, Czuczman MS. Use of rituximab, the new PDA-approved antibody. Curr Opin Oncol. 1998;10:548-551.
2. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484-1492.
3. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis. 2003;62(Suppl 2):55-59.
4. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (DDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
5. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803-843.
6. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40:205-211.
7. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581.
8. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002;46:2029-2033.
9. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:883-888.
10. Du Bois D, Du Bois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863-871.
11. Mangel J, Buckstein R, Imrie K, et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol. 2003;14:758-765.
12. Boeckmann AJ, Beal SL. NONMEM User Guide. San Francisco: NONMEM Project Group, University of California, San Francisco; 1994.
13. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-252.
14. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1-110.
15. Colburn WA. Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic/toxicologic effects of drugs. Drug Metab Rev. 1980;11:223-262.
16. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
17. Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003;123:850-857.
18. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologie malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791-795.